| | | Publisher’s Note: Join Fierce Biotech Editors and industry leaders at the Fierce Biotech Summit to network and gain exclusive insights. Don’t miss out — register now! |
Today’s Big News Sep 9, 2024 |
| Still Time to Shine! Submission deadline for the Fierce Life Sciences Innovation Awards have been extended to September 12. Click to submit your entry and learn more about what winner's will receive.
|
|
| | | By Ayla Ellison In this year's Fierce 50 special report, we are highlighting the innovators and leaders who are shaping the future of healthcare, pharma and biotechnology. This year's honorees demonstrate unwavering dedication and creativity, propelling these industries forward. |
|
|
|
| By James Waldron The study missed the primary endpoint of demonstrating an improvement in pre-bronchodilator forced expiratory volume (FEV), the amount of air that a person can exhale during a forced breath, compared with placebo. |
| By Darren Incorvaia After overseeing the $4.1 billion sale of radiopharma player RayzeBio to Bristol Myers Squibb, biotech veteran Ken Song, M.D., didn’t take long to set up his next big venture. He is now chairman, president and CEO of Candid Therapeutics, which has debuted with a $370 million series A and a goal to dominate the T-cell engager market. |
| By Nick Paul Taylor Merck & Co.’s long-running effort to land a punch on small cell lung cancer (SCLC) has racked up a small victory. The drugmaker’s Daiichi Sankyo-partnered antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd) showed promise in the setting, offering encouragement as a late-stage trial progresses. |
| Partner with us for vaccine manufacturing that expertly integrates novel analytical and process-related technologies with your program's unique needs, ensuring efficient tech transfer and rapid scaling. Grow with us.
|
|
| By Angus Liu The Keytruda-beating data from Akeso and Summit’s ivonescimab that oncology industry watchers had been awaiting are here. The China-only data are impressive, signaling the PD-1/VEGF bispecific antibody’s potential as a new standard of care in non-small cell lung cancer. |
| By James Waldron GSK’s long-acting asthma treatment has been shown to halve the number of attacks in a pair of phase 3 trials, supporting the Big Pharma’s push toward approval despite falling short on a some secondary endpoints. |
| By James Waldron Terns Pharmaceuticals’ decision to drop its liver disease ambitions may yet pay off, after the biotech posted phase 1 data showing one of its other candidates induced 5% weight loss in a month. |
| By Nick Paul Taylor Relay Therapeutics has beaten its survival goal in a first-in-human breast cancer study, positioning the biotech to move into a pivotal trial that could establish its candidate as a challenger to AstraZeneca’s Truqap. |
| By Darren Incorvaia Just over a year after securing $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A round featuring the likes of Eli Lilly. |
| By James Waldron MBX has fleshed out plans to take in over $136 million from its IPO as the biotech looks to take a potential challenger to Ascendis Pharma’s rare endocrine disease drug Yorvipath into phase 3. |
| By Angus Liu Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better challenge AstraZeneca’s Tagrisso. |
| By Conor Hale Think Surgical collected its third FDA clearance in as many months, with the latest being a specialized version of its knee replacement system paired with Zimmer Biomet. |
Fierce podcasts Don’t miss an episode |
| | | In this week's episode of "Podnosis," two experts break down the history of plastics use in the healthcare sector and what it would take for an organization to phase them out. |
|
|---|
|
|
| Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
| Whitepaper We interviewed dozens of biopharma leaders on the critical success factors for building a Best Practice commercial organization. This report shares what we learned. Sponsored by: Blue Matter Consulting |
| Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
| On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| | |
|
